The 21-gene Oncotype DX Breast Recurrence Score® assay is a validated prognostic/predictive tool used to guide adjuvant treatment decisions in estrogen receptor (ER)+ HER2-negative early breast cancer (BC).1–7 The initial validation used a prospective–retrospective design. The gene discussed is ESR1; the disease is breast cancer.